XOMA Royalty Boosts Portfolio with 22 New Assets, Eyes Key 2026 Catalysts
Event summary
- XOMA Royalty reported $50.5M in cash receipts for 2025, up 9% YoY, with royalties increasing 68% to $33.6M.
- Added 22 assets to its portfolio, including five in Phase 2 or 3 development, and completed seven acquisitions.
- Repurchased 648,048 shares for $16M and secured $11.7M in non-dilutive capital from acquisitions.
- Key 2026 pipeline events include Phase 2b data for volixibat in PSC and Phase 3 data for ersodetug in tumor HI.
- Day One's OJEMDA received a positive CHMP opinion from the EMA and was acquired by Servier for $2.5B.
The big picture
XOMA Royalty's 2025 financial results highlight its strategy of portfolio expansion through acquisitions and royalty aggregation. The company's ability to secure non-dilutive capital and repurchase shares underscores its financial flexibility. As biotech royalty aggregators face increasing competition, XOMA's focus on late-stage assets and regulatory catalysts positions it to capitalize on growing royalty streams. The acquisition of Day One by Servier for $2.5B further validates the value of XOMA's portfolio strategy.
What we're watching
- Regulatory Catalysts
- The pace at which XOMA's key pipeline assets, including volixibat and ersodetug, secure regulatory approvals will determine royalty stream growth.
- Acquisition Strategy
- Whether XOMA can sustain its aggressive acquisition pace while maintaining financial discipline will be critical for long-term value creation.
- Portfolio Diversification
- How the addition of 22 new assets, including five in late-stage development, will diversify XOMA's revenue streams and mitigate risk.
Related topics